Investigating the correlations between substance P, antioxidant levels, and metabolic markers in non-obese Type 2 Diabetic patients

Abstract

Hyperglycemia and hyperinsulinemia in type 2 diabetes mellitus (T2DM) result in complications exacerbated by oxidative stress, leading to cardiovascular, nephropathic, neuropathic, and retinopathic complications. Substance P (SP), a natural neuropeptide, inhibits cell death and enhances cell growth during oxidative or inflammatory stress, suggesting a potential role in reducing diabetic complications. The current study aimed to investigate serum levels of total antioxidant status (TAS), SP, glycemic measures, and lipid profiles in non-obese T2DM patients and evaluate the correlations involving these biomarkers in a case-control study involving eighty-five adult participants (46 males and 39 females), aged (30-60) years, and were divided into two groups; 53 non-obese T2DM patients, and 32 Apparently healthy individuals of matching age, sex and body mass index to the patients group. The results showed that patients' glucose levels increased as a percentage increase of (˃141%), mild elevated insulin levels (˃50%), higher insulin resistance (˃250%), the lipid parameters exhibited disruption comparing to the control group, in the diabetic group, the serum levels of TAS, SP decreased considerably in comparison to the control group. As evidenced by the outcomes; the TAS showed significant negative correlations with fasting serum glucose and low-density lipoprotein and positive correlations with high-density lipoprotein. Neither the glycemic indices nor the lipid profiles or TAS demonstrated any notable associations with SP levels. This suggests that while SP levels are reduced in T2DM patients, they do not appear to be directly linked with the measured biomarkers.

Keywords

• Lipid profile
• Oxidative stress
• Substance P
• Total Antioxidant Status
• T2DM

References

1. [1] Raheem MF, Ali SH, AL-Nuaimi AMA, Shareef LG. Impact of serum vitamin D level on selected bone-related markers in obese- Type 2 Diabetes Patients. F1000Res 2023; 12: 56. http://doi.org/10.12688/f1000research.126650.1
2. [2] Yaas AA, Al-Shakour AA, Mansour AA. Assessment of serum level of protein carbonyl as a marker of protein oxidation in patients with Type 2 Diabetes Mellitus. Al-Kindy Col Med J. 2022;18:190–195. http://doi.org/10.47723/kcmj.v18i3.827
3. [3] Abed BA, Farhan LO, Dawood AS. Relationship between Serum Nesfatin-1, Adiponectin, Resistin Concentration, and Obesity with Type 2 Diabetes Mellitus. Baghdad Sci J. 2023;21(1):0117. http://doi.org/10.21123/bsj.2023.8119
4. [4] Jaid HK, Khaleel FM, Salman, IN, Abd BA. Estimation of Apelin Levels in Iraqi Patients with Type II Diabetic Peripheral Neuropathy. Baghdad Sci J. 2023;1;20(5):1684. http://doi.org/10.21123/bsj.2023.7566
5. [5] Abdulrahman AJ, Jabarah MAH, Najjar SA. Effects of liraglutide on weight control and blood pressure in Type 2 Diabetes Mellitus Iraqi Patients. J Fac Med Baghdad. 2023;64(4):227–232. http://doi.org/10.32007/jfacmedbagdad.6441971
6. [6] El-Mesallamy HO, Hamdy NM, Sallam AA. Effect of obesity and glycemic control on serum lipocalins and insulin- like growth factor axis in type 2 diabetic patients. Acta Diabetol. 2013;50(5):679-685. http://doi.org/10.1007/s00592- 012-0373-6
7. [7] Bhambhani G, Bhambhani R, Thakor N. Lipid profile of patients with Diabetes Mellitus: A cross sectional study. Int J Res Med Sci 2015, 3292–3295. http://doi.org/10.18203/2320-6012.ijrms20151179
8. [8] Burgos-Morón E, Abad-Jiménez Z, Marañón AM, Iannantuoni F, Escribano-López I, López-Domènech S, Salom C, Jover A, Mora V, Roldan I, Solá E, Rocha M, Víctor VM. Relationship between oxidative stress, ER Stress, and ınflammation in Type 2 Diabetes: The battle continues. J Clin Med. 2019;8(9):1385. http://doi.org/10.3390/jcm8091385

9. [9] Park JS, Piao J, Park G, Hong HS. Substance-P restores cellular activity of ADSC ımpaired by oxidative stress. Antioxidants (Basel). 2020;9(10):978. http://doi.org/10.3390/antiox9100978
10. [10] Kim DY, Piao J, Hong HS. Substance-P ınhibits cardiac microvascular endothelial dysfunction caused by high glucose-ınduced oxidative stress. Antioxidants (Basel). 2021;10(7):1084. http://doi.org/10.3390/antiox10071084
11. [11] Hamdy NM, Suwailem SM, El-Mesallamy HO. Influence of vitamin E supplementation on endothelial complications in type 2 diabetes mellitus patients who underwent coronary artery bypass graft. J Diabetes Complications. 2009;23(3):167-173. http://doi.org/10.1016/j.jdiacomp.2007.10.006
12. [12] Pasupuleti VR, Arigela CS, Gan SH, Salam SKN, Krishnan KT, Rahman NA, Jeffree MS. A review on oxidative stress, diabetic complications, and the roles of honey polyphenols. Oxid Med Cell Longev. 2020;2020:8878172. http://doi.org/10.1155/2020/8878172
13. [13] Silvestrini A, Meucci E, Ricerca BM, Mancini A. Total antioxidant capacity: Biochemical aspects and clinical significance. Int J Mol Sci. 2023;24(13):10978. http://doi.org/10.3390/ijms241310978
14. [14] Prasad PS. Hyperglycaemia and inflammation are prime factors to persuade endothelial dysfunction in patients with Type 2 Diabetes Mellitus. Indian J Public Health Res Dev. 2020;11:288–293. http://doi.org/10.37506/ijphrd.v11i5.9335
15. [15] Patel BJ, Dave B, Dave D, Karmakar P, Shah M, Sarvaiya B. Comparison and correlation of glucose levels in serum and saliva of both diabetic and non-diabetic patients. J Int Oral Health. 2015;7(8):70-76.
16. [16] Kadhim SA, Saleh ES, Jaafer AD. Assessment of serum levels of advanced oxidation protein products in Type 2 Diabetic patients with and without retinopathy taking different antidiabetic treatments. Iraqi J Pharm Sci. 2023; 32: 74–82. http://doi.org/10.31351/vol32iss2pp74-82
17. [17] Lee J, Kim MH, Jang JY, Oh CM. Assessment HOMA as a predictor for new onset diabetes mellitus and diabetic complications in non-diabetic adults: a KoGES prospective cohort study. Clin Diabetes Endocrinol. 2023;9(1):7. http://doi.org/10.1186/s40842-023-00156-3
18. [18] Ali IA, Ali SH. Impact of osteocalcin level on vascular calcification in Type 2 Diabetics in relation to Fibroblast Growth Factor-23(FGF-23). Iraqi J Pharm Sci. 2018; 27(2):42–54. http://doi.org/10.31351/vol27iss2pp42-54
19. [19] Marita AR, Sarkar JA, Rane S. Type 2 diabetes in non-obese Indian subjects is associated with reduced leptin levels: Study from Mumbai, Western India. Mol Cell Biochem. 2005;275(1-2):143-151. http://doi.org/10.1007/s11010-005- 1204-7
20. [20] Olaogun I, Farag M, Hamid P. The pathophysiology of Type 2 Diabetes Mellitus in non-obese ındividuals: An overview of the current understanding. Cureus. 2020;12(4):e7614. http://doi.org/10.7759/cureus.7614.
21. [21] Sherwani SI, Khan HA, Ekhzaimy A, Masood A, Sakharkar MK. Significance of HbA1c test in diagnosis and prognosis of Diabetic Patients. Biomark Insights. 2016;11:95-104. http://doi.org/10.4137/BMI.S38440.
22. [22] Valizadeh R, Moosazadeh M, Bahaadini K, Vali L, Lashkari T, Amiresmaili M. Determining the prevalence of retinopathy and ıts related factors among patients with Type 2 Diabetes in Kerman, Iran. Osong Public Health Res Perspect. 2016;7(5):296-300. http://doi.org/10.1016/j.phrp.2016.08.004
23. [23] Raheem MF, Ali SH, Shareef LG. Impact of serum levels of vitamin D on lipid profiles, glycemic indices, and insulin resistance in obese Type 2 Diabetes Patients: An observational study. F1000Res. 2022;11:1002. http://doi.org/10.12688/f1000research.125191.1
24. [24] Alaaraji SF, Alrawi KF, Allah PHS, Alkrwi EN. Evaluation of serum malondialdehyde, glutathione and lipid profile levels in Iraqi Females with Type 2 Diabetes Mellitus. Baghdad Sci J. 2016;13:0383. http://doi.org/10.21123/bsj.2016.13.2.2NCC.0383
25. [25] Chen SC, Tseng CH. Dyslipidemia, kidney disease, and cardiovascular disease in diabetic patients. Rev Diabet Stud. 2013;10(2-3):88-100. http://doi.org/10.1900/RDS.2013.10.88
26. [26] Biadgo B, Abebe SM, Baynes HW, Yesuf M, Alemu A, Abebe M. Correlation between serum lipid profile with anthropometric and clinical variables in patients with Type 2 Diabetes Mellitus. Ethiop J Health Sci. 2017;27(3):215- 226. http://doi.org/10.4314/ejhs.v27i3.3
27. [27] Boussekine S, Menaceur F, Gasmi S, Lidoughi A, Rais T, Gattel H. Oxidative stress assessment and its relationship with the prevalence of atherogenic risk in patients with type 2 diabetes. J Diabetes Metab Disord. 2021;20(1):583-590. http://doi.org/10.1007/s40200-021-00785-4
28. [28] Sies H, Belousov VV, Chandel NS, Davies MJ, Jones DP, Mann GE, Murphy MP, Yamamoto M, Winterbourn C. Defining roles of specific reactive oxygen species (ROS) in cell biology and physiology. Nat Rev Mol Cell Biol. 2022;23(7):499-515. http://doi.org/10.1038/s41580-022-00456-z.
29. [29] Rani AJ. Study on Total Antioxidant Status in Relation to Oxidative Stress in Type 2 Diabetes Mellitus. J Clin Diagn Res. 2014;8(3):108-110.http://doi.org/10.7860/JCDR/2014/7603.4121.
30. [30] Picchi A, Capobianco S, Qiu T, Focardi M, Zou X, Cao JM, Zhang C. Coronary microvascular dysfunction in diabetes mellitus: A review. World J Cardiol. 2010;2(11):377-390. http://doi.org/10.4330/wjc.v2.i11.377
31. [31] Srivatsan R, Das S, Gadde R, Manoj-Kumar K, Taduri S, Rao N, Ramesh B, Baharani A, Shah K, Kamireddy SC, Priyatham G, Balakumaran TA, Balakumaran SS, Kamath A, Rao A. Antioxidants and lipid peroxidation status in diabetic patients with and without complications. Arch Iran Med. 2009;12(2):121-127.
32. [32] Kokabi F, Ebrahimi S, Mirzavi F, Ghiasi Nooghabi N, Hashemi SF, Hashemy SI. The neuropeptide substance P/neurokinin-1 receptor system and diabetes: From mechanism to therapy. Biofactors. 2023;49(3):534-559. http://doi.org/10.1002/biof.1935.
33. [33] Kadota T, Kakuta N, Horikawa YT, Tsutsumi R, Oyama T, Tanaka K, Tsutsumi YM. Plasma substance P concentrations in patients undergoing general anesthesia: An objective marker associated with postoperative nausea and vomiting. JA Clin Rep. 2016;2(1):9. https://doi.org/10.1186/s40981-016-0034-9
34. [34] Yan L, Zhang R, Guo Z. Relationship between plasma substance P and calcitonin gene-related peptide concentrations and intraoperative cardiovascular events in Diabetic Patients. Chinese Asian J Anesthesiol . 2017;12:649–652.
35. [35] Wang LH, Zhou SX, Li RC, Zheng LR, Zhu JH, Hu SJ, Sun YL. Serum levels of calcitonin gene-related peptide and substance P are decreased in patients with diabetes mellitus and coronary artery disease. J Int Med Res. 2012;40(1):134-140. http://doi.org/10.1177/147323001204000114
36. [36] Fu J, Liu B, Liu P, Liu L, Li G, Wu B, Liu X. Substance P is associated with the development of obesity, chronic inflammation and type 2 diabetes mellitus. Exp Clin Endocrinol Diabetes. 2011;119(3):177-181. http://doi.org/10.1055/s-0030-1261965
37. [37] Kunt T, Forst T, Schmidt S, Pfützner A, Schneider S, Harzer O, Löbig M, Engelbach M, Goitom K, Pohlmann T, Beyer J. Serum levels of substance P are decreased in patients with type 1 diabetes. Exp Clin Endocrinol Diabetes. 2000;108(3):164-167. http://doi.org/10.1055/s-2000-7738
38. [38] Leal EC, Carvalho E, Tellechea A, Kafanas A, Tecilazich F, Kearney C, Kuchibhotla S, Auster ME, Kokkotou E, Mooney DJ, LoGerfo FW, Pradhan-Nabzdyk L, Veves A. Substance P promotes wound healing in diabetes by modulating inflammation and macrophage phenotype. Am J Pathol. 2015;185(6):1638-1648. http://doi.org/10.1016/j.ajpath.2015.02.011
39. [39] Yaribeygi H, Atkin SL, Sahebkar A. A review of the molecular mechanisms of hyperglycemia-induced free radical generation leading to oxidative stress. J Cell Physiol. 2019;234(2):1300-1312. http://doi.org/10.1002/jcp.27164
40. [40] Baharirad N, Pasdar Y, Nachvak M, Ghavamzadeh S, Soroush A, Saber A, Mostafai S, Naghipour A, Abdollahzad H. The relationship of dietary total antioxidant capacity with sarcopenia and cardiometabolic biomarkers in type 2 diabetes patients. Physiol Rep. 2022;10(3):e15190. http://doi.org/10.14814/phy2.15190
41. [41] Piechota W. Lipid peroxidation, total antioxidant status, and glycemic control in patients with type 2 diabetes mellitus. Mil Physician. 2018;96(1):14-18.
42. [42] Najafi A, Pourfarzam M, Zadhoush F. Oxidant/antioxidant status in Type-2 diabetes mellitus patients with metabolic syndrome. J Res Med Sci. 2021;26:6. http://doi.org/10.4103/jrms.JRMS_249_20
43. [43] Bonilha I, Zimetti F, Zanotti I, Papotti B, Sposito AC. Dysfunctional high-density lipoproteins in Type 2 Diabetes Mellitus: Molecular mechanisms and therapeutic ımplications. J Clin Med. 2021;10(11):2233. http://doi.org/10.3390/jcm10112233
44. [44] Nour Eldin EE, Almarzouki A, Assiri AM, Elsheikh OM, Mohamed BE, Babakr AT. Oxidized low density lipoprotein and total antioxidant capacity in type-2 diabetic and impaired glucose tolerance Saudi men. Diabetol Metab Syndr. 2014;6(1):94. http://doi.org/10.1186/1758-5996-6-94
45. [45] Blackburn, H.; Jacobs, D. Commentary: Origins and evolution of body mass index (BMI): Continuing Saga. Int J Epidemiol 2014; 43: 665–669. http://doi.org/10.1093/ije/dyu061
46. [46] Aldafaay AAA, Abdulamir HA, Abdulhussain HA, Badry AS, Abdulsada AK. The use of urinary α-amylase level in a diagnosis of chronic renal failure. Res J Pharm Technol. 2021; 14(3):1597-1600. http://dx.doi.org/10.5958/0974- 360X.2021.00283.3.
47. [47] Abdulhussein HA, Alwasiti EA, Khiro NK, Nile AK. The potential impact of vascular endothelial growth factor rs699947 polymorphisms on breast tumors susceptibility in a sample of Iraqi females. Acta Pharm Sci. 2024;62(2):268- 277. http://dx.doi.org/10.23893/1307.APS6217.
48. [48] Hamdy NM, Suwailem SM, El-Mesallamy HO. Influence of vitamin E supplementation on endothelial complications in type 2 diabetes mellitus patients who underwent coronary artery bypass graft. J Diabetes Complications. 2009;23(3):167-173. http://doi.org/10.1016/j.jdiacomp.2007.10.006.